As expected, the Xianhecao-Huanglian drug pair inhibited the secretion of TNF-α, IL-1β, and also IL-6 in the colonic tissues and serum of IBD-afflicted mice, while augmenting IL-10 secretion. Here, IL10 is linked to inflammatory bowel disease.